CBD Labeling Requirements: Federal Elements, THC, and Claims

CBD labeling requirements sit on top of an unresolved federal question: hemp-derived CBD is legal to grow and process under the 2018 Farm Bill, but the FDA still does not recognize CBD as a lawful food additive or dietary supplement ingredient. That gap does not excuse you from labeling law. If you manufacture or sell a CBD product, your label must carry the four elements required by the Fair Packaging and Labeling Act, use the correct nutrition or supplement panel, keep every health claim within tight limits, disclose accurate THC content, and satisfy whatever additional rules apply in each state where the product is sold.

The Four Federal Label Elements

Any consumer commodity sold in the United States must comply with the Fair Packaging and Labeling Act, which requires four items on every package: a statement of identity, the net quantity of contents, the name and place of business of the responsible company, and an ingredient list.¹

Statement of Identity

The label must tell the consumer what the product actually is, using the common or usual name or a descriptive term that includes the product’s function when no standard name exists.² For a CBD product, that could read “hemp extract tincture” or “broad-spectrum CBD topical.” The identity statement has to appear as a principal feature of the front panel, in legible type that contrasts with the background, oriented parallel to the base of the package.

Net Quantity of Contents

A separate front-panel declaration must state how much product is inside. The measurement can be expressed as weight, liquid volume, or count, and it must include both customary units (ounces, fluid ounces) and metric units (grams, milliliters).² For food-type products, this declaration must sit within the bottom 30 percent of the front panel.³ Packages with a front panel of five square inches or less are exempt from that placement rule, but the declaration itself still has to be there.

Name and Place of Business

Every label must identify who is responsible for the product. Regulation 21 CFR 101.5 requires the name of the manufacturer, packer, or distributor along with a street address, city, state, and ZIP code.⁴ The street address can be omitted only if it already appears in a current city directory or telephone directory. If the company named did not actually manufacture the product, the label needs a qualifier like “Distributed by” or “Manufactured for.” That contact information doubles as the address consumers use to report serious adverse events.

Ingredient List

List every ingredient by its common or usual name in descending order of predominance by weight.⁵ For CBD products, that generally covers the carrier oil, flavoring agents, preservatives, and the hemp extract itself. Common allergens have to be clearly identified.

Supplement Facts or Nutrition Facts

Which panel your product needs depends on how it is categorized. Products marketed as dietary supplements use a Supplement Facts panel; conventional foods use a Nutrition Facts panel. The two are not interchangeable.⁶

A Supplement Facts panel lists the name and quantity of each dietary ingredient, the serving size (the maximum amount recommended per eating occasion), and the servings per container. For each botanical ingredient, the panel must identify the plant part used. The source of a dietary ingredient may also be listed. A Nutrition Facts panel does not permit ingredients that lack established daily reference values, and it requires “zero” declarations for certain nutrients that the Supplement Facts panel does not.

Here is where CBD sits awkwardly. Most CBD products on the market carry Supplement Facts panels, but the FDA has concluded that CBD is not a lawful dietary supplement ingredient because it is an active ingredient in the FDA-approved drug Epidiolex, and because the agency has not established safe consumption levels.⁷ Positioning the same product as a conventional food with added CBD swaps one problem for a worse one: adding CBD to food is directly prohibited under the Federal Food, Drug, and Cosmetic Act.⁸ No panel format solves the underlying legal gap; the FDA is operating on enforcement discretion.

Placement and Readability

The principal display panel is the part of the label most likely to be seen by a consumer when the product is displayed for sale.⁹ The statement of identity and net quantity of contents both go here. The information panel, which carries the ingredient list, nutrition or supplement information, and business address, sits immediately to the right of the principal display panel as a consumer faces the package.¹⁰ If the space to the right is unusable, the next adjacent panel may serve instead.

All mandatory text on either panel must be at least one-sixteenth of an inch tall, printed in a color that clearly contrasts with the background.¹⁰ A product that fails these standards can be treated as misbranded, and misbranding violations carry criminal penalties under 21 USC 333.

Health Claims: What You Cannot Say

This is where most CBD companies get into trouble. The FDA has stated that marketing a CBD product as a treatment for any disease makes it an unapproved new drug, which is illegal to sell without going through the formal drug approval process.⁸ Claims that a CBD product treats cancer, relieves anxiety disorders, cures chronic pain, or prevents Alzheimer’s disease have all triggered warning letters. The agency continues issuing them, with enforcement actions as recently as 2025.¹¹

Many CBD labels carry the familiar disclaimer, “This product is not intended to diagnose, treat, cure, or prevent any disease.” That language comes from the dietary supplement framework, where it is required alongside any structure/function claim (a claim about how a product affects the body’s normal processes, such as “supports joint health”). A manufacturer using such a claim must notify the FDA within 30 days of first marketing the product and display the disclaimer prominently.¹² The catch: because the FDA does not consider CBD a lawful supplement ingredient, this disclaimer does not provide the safe harbor many companies assume. It is better than an unqualified disease claim, but it does not immunize the product.

The Federal Trade Commission polices the same territory from the advertising side. In a coordinated 2020 action, the FTC settled with six companies over unsupported health claims about CBD products, and subsequent violations of an FTC order can carry civil penalties exceeding $43,000 each.¹³ The FTC’s evidentiary standard is competent and reliable scientific evidence, including human clinical testing, for any health-related claim. Vague wellness language such as “promotes relaxation” occupies a gray zone; specific disease claims are a guaranteed enforcement trigger.

THC Content on the Label

The Farm Bill’s 0.3 percent THC threshold is calculated as total THC, not just the delta-9 THC in a sample. Total THC accounts for THCA (the acidic precursor in raw plant material) converting into active delta-9 THC when heated or processed.¹⁴

The USDA requires labs to use post-decarboxylation testing methods, or to apply a mathematical conversion: total THC equals the measured delta-9 THC plus 87.7 percent of the THCA content.¹⁵ A finished product can test low in delta-9 THC and still exceed 0.3 percent once the THCA is factored in. Labels that report only delta-9 THC risk misleading both consumers and regulators.

Third-Party Testing and Certificates of Analysis

No federal statute specifically requires a QR code linking to lab results, but the practice has become a baseline industry expectation, and a growing number of states require it as a condition of sale. A Certificate of Analysis documents what an independent lab found in a specific production batch: the cannabinoid profile confirming CBD potency and total THC below 0.3 percent, plus screening for heavy metals, pesticides, and residual solvents.

When a QR code appears on a label, it should link to results that match the specific batch, identified by a batch or lot number and a testing date. If those details do not align with the product in a consumer’s hand, the certificate is meaningless. The recognized international standard for lab competence is ISO/IEC 17025. Full-panel potency and purity testing for a single batch generally runs $500 to $600, a cost worth building into per-unit pricing rather than skipping.

Adverse Event Reporting Contact

If your product is marketed as a dietary supplement, the “responsible person” whose name appears on the label must report serious adverse events to the FDA within 15 business days of receiving them.¹⁶ The clock starts when a report comes in through the address or phone number printed on the label, so the label must include a domestic contact address or phone number for that purpose.¹⁷ If a retailer’s name appears as the distributor, the retailer can authorize the manufacturer to handle reporting on its behalf, but the retailer stays responsible for forwarding anything it receives.

State Rules That Go Beyond the Federal Baseline

State regulations frequently exceed federal requirements and differ from state to state. Some states require every unit sold to include a scannable link to a Certificate of Analysis. Others require formal product registration with the state agriculture department before any retail sale. Serving-size instructions, age warnings, and pregnancy or nursing advisories appear in many state rules even though no single federal rule mandates them for CBD.

A survey of labeling rules in states with medical cannabis programs found that roughly three-quarters required an expiration or best-by date, and some states require a universal cannabinoid symbol whose design differs by jurisdiction. Requirements can also differ between product types within the same state. A label designed for one state may be noncompliant in another, so companies distributing nationally either design to the most restrictive state’s rules or maintain region-specific packaging.

Penalties for Getting It Wrong

Under the FD&C Act, a first misbranding offense can result in up to one year of imprisonment and a $1,000 fine. A repeat offense, or one involving intent to defraud or mislead, carries up to three years and $10,000.¹⁸ The FDA can also seek injunctions and seize misbranded goods.

FTC penalties layer on separately: violations of an FTC order can exceed $43,000 each.¹³ State penalties vary but can include per-product fines, mandatory recalls, and loss of the right to sell in that state. For a company selling multiple SKUs across several states, a single labeling mistake compounds fast.

1
Office of the Law Revision Counsel. 15 USC Chapter 39 – Fair Packaging and Labeling Program
2
eCFR. 16 CFR Part 500 – Regulations Under Section 4 of the Fair Packaging and Labeling Act
3
eCFR. 21 CFR 101.7 – Declaration of Net Quantity of Contents
4
eCFR. 21 CFR 101.5 – Food; Name and Place of Business of Manufacturer, Packer, or Distributor
5
eCFR. 21 CFR 101.4 – Food; Designation of Ingredients
6
U.S. Food and Drug Administration. Dietary Supplement Labeling Guide: Chapter IV – Nutrition Labeling
7
U.S. Food and Drug Administration. FDA Concludes That Existing Regulatory Frameworks for Foods and Supplements Are Not Appropriate for Cannabidiol
8
U.S. Food and Drug Administration. FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD)
9
eCFR. 21 CFR 101.1 – Principal Display Panel of Package Form Food
10
eCFR. 21 CFR 101.2 – Information Panel of Package Form Food
11
U.S. Food and Drug Administration. Warning Letters for Cannabis-Derived Products
12
U.S. Food and Drug Administration. Structure/Function Claim Notification for Dietary Supplements – Electronic Submissions
13
Federal Trade Commission. FTC Announces Crackdown on Deceptively Marketed CBD Products
14
Federal Register. Establishment of a Domestic Hemp Production Program
15
Agricultural Marketing Service (USDA). Laboratory Testing Guidelines – U.S. Domestic Hemp Production Program
16
Office of the Law Revision Counsel. 21 USC 379aa-1 – Serious Adverse Event Reporting for Dietary Supplements
17
U.S. Food and Drug Administration. Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements
18
Office of the Law Revision Counsel. 21 USC 333 – Penalties